Theravance Biopharma (TBPH) Competitors $10.69 +0.08 (+0.75%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$10.70 +0.01 (+0.05%) As of 06/13/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TBPH vs. AAPG, NAMS, BLTE, HRMY, KNSA, VERA, GMTX, LGND, GLPG, and FOLDShould you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Ascentage Pharma Group International (AAPG), NewAmsterdam Pharma (NAMS), Belite Bio (BLTE), Harmony Biosciences (HRMY), Kiniksa Pharmaceuticals (KNSA), Vera Therapeutics (VERA), Gemini Therapeutics (GMTX), Ligand Pharmaceuticals (LGND), Galapagos (GLPG), and Amicus Therapeutics (FOLD). These companies are all part of the "pharmaceutical preparations" industry. Theravance Biopharma vs. Its Competitors Ascentage Pharma Group International NewAmsterdam Pharma Belite Bio Harmony Biosciences Kiniksa Pharmaceuticals Vera Therapeutics Gemini Therapeutics Ligand Pharmaceuticals Galapagos Amicus Therapeutics Ascentage Pharma Group International (NASDAQ:AAPG) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, community ranking, valuation, dividends and profitability. Do analysts prefer AAPG or TBPH? Theravance Biopharma has a consensus target price of $11.33, indicating a potential upside of 6.02%. Given Theravance Biopharma's higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Theravance Biopharma 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Is AAPG or TBPH more profitable? Ascentage Pharma Group International has a net margin of 0.00% compared to Theravance Biopharma's net margin of -78.18%. Ascentage Pharma Group International's return on equity of 0.00% beat Theravance Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group InternationalN/A N/A N/A Theravance Biopharma -78.18%-24.79%-13.43% Does the MarketBeat Community prefer AAPG or TBPH? Theravance Biopharma received 342 more outperform votes than Ascentage Pharma Group International when rated by MarketBeat users. However, 100.00% of users gave Ascentage Pharma Group International an outperform vote while only 62.94% of users gave Theravance Biopharma an outperform vote. CompanyUnderperformOutperformAscentage Pharma Group InternationalOutperform Votes1100.00% Underperform VotesNo VotesTheravance BiopharmaOutperform Votes34362.94% Underperform Votes20237.06% Which has preferable earnings and valuation, AAPG or TBPH? Ascentage Pharma Group International has higher revenue and earnings than Theravance Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscentage Pharma Group International$980.65M2.80N/AN/AN/ATheravance Biopharma$65.27M8.19-$55.19M-$1.18-9.06 Do insiders and institutionals hold more shares of AAPG or TBPH? 99.1% of Theravance Biopharma shares are owned by institutional investors. 6.9% of Theravance Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor AAPG or TBPH? In the previous week, Ascentage Pharma Group International had 2 more articles in the media than Theravance Biopharma. MarketBeat recorded 4 mentions for Ascentage Pharma Group International and 2 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.88 beat Ascentage Pharma Group International's score of 0.73 indicating that Theravance Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascentage Pharma Group International 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryAscentage Pharma Group International beats Theravance Biopharma on 7 of the 13 factors compared between the two stocks. Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TBPH vs. The Competition Export to ExcelMetricTheravance BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$534.51M$6.88B$5.57B$8.51BDividend YieldN/A2.51%5.27%4.16%P/E Ratio-10.588.5026.7819.65Price / Sales8.19263.11404.49152.18Price / CashN/A65.8538.2534.64Price / Book2.506.526.964.59Net Income-$55.19M$143.48M$3.23B$248.23M7 Day Performance-4.98%-0.20%-1.24%-1.07%1 Month Performance27.11%11.63%8.34%3.35%1 Year Performance26.06%3.21%33.30%13.77% Theravance Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TBPHTheravance Biopharma0.8655 of 5 stars$10.69+0.8%$11.33+6.0%+24.6%$534.51M$65.27M-10.58359Positive NewsAAPGAscentage Pharma Group InternationalN/A$25.22+3.4%N/AN/A$2.20B$980.65M0.00600NAMSNewAmsterdam Pharma2.9682 of 5 stars$18.93+4.5%$43.00+127.2%+4.0%$2.13B$47.14M-10.074Analyst ForecastAnalyst RevisionBLTEBelite Bio2.795 of 5 stars$65.02+0.2%$96.67+48.7%+18.9%$2.07BN/A-58.5810Positive NewsShort Interest ↑Analyst RevisionHRMYHarmony Biosciences4.7664 of 5 stars$35.56+3.1%$53.00+49.0%+10.8%$2.04B$744.85M16.85200Positive NewsShort Interest ↑Analyst RevisionKNSAKiniksa Pharmaceuticals3.25 of 5 stars$27.92+2.0%$38.80+39.0%+50.9%$2.04B$481.17M-199.41220Analyst UpgradeInsider TradeVERAVera Therapeutics3.0357 of 5 stars$31.74+67.5%$65.00+104.8%-39.2%$2.02BN/A-12.1640Short Interest ↑Analyst RevisionHigh Trading VolumeGMTXGemini TherapeuticsN/A$46.68-0.4%N/A+34.6%$2.02BN/A-46.6830News CoverageHigh Trading VolumeLGNDLigand Pharmaceuticals4.3949 of 5 stars$101.64-0.5%$146.14+43.8%+38.3%$1.96B$181.49M40.4980News CoveragePositive NewsGLPGGalapagos0.2639 of 5 stars$29.20+1.5%$25.33-13.2%+11.8%$1.92B$288.19M0.001,310FOLDAmicus Therapeutics4.0732 of 5 stars$6.16+1.5%$16.22+163.3%-43.4%$1.90B$543.14M-34.22480 Related Companies and Tools Related Companies AAPG Alternatives NAMS Alternatives BLTE Alternatives HRMY Alternatives KNSA Alternatives VERA Alternatives GMTX Alternatives LGND Alternatives GLPG Alternatives FOLD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TBPH) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
